Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma

Abstract The role of the epidermal growth factor receptor (EGFR) mutation status testing in lung squamous cell carcinoma (SqCC) remains controversial. Evidence of the effectiveness of osimertinib in SqCC with EGFR T790M mutation is limited. Here, we describe a hitherto unreported case of a stage III...

Full description

Bibliographic Details
Main Authors: MuYun Peng, QiuYuan Wen, Xia Wu, FengLei Yu, WenLiang Liu
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Thoracic Cancer
Subjects:
Online Access:https://doi.org/10.1111/1759-7714.13431